Background {#Sec1}
==========

According to the Global Cancer Statistics report of the year 2018, cervical cancer ranks 4th for both incidence and mortality with over 570,000 cases and 311,000 deaths worldwide \[[@CR1]\]. The global burden of cervical cancer (close to 85%) occurs in developing countries, where it accounts for about 12% of all female cancers \[[@CR1], [@CR2]\]; and nine out of ten cervical cancer deaths disproportionately occur in developing countries \[[@CR3]--[@CR9]\].

About 95--99% of cervical cancer cases are associated with genital infection with High risk (HR)-HPV, which is the most common viral infection of the reproductive tract globally \[[@CR10], [@CR11]\] that most women are experiencing soon after they become sexually active \[[@CR12]\]. Persistent infection with HR-HPV is the primary cause of cervical cancer and its precursor lesion, called the cervical intraepithelial neoplasia (CIN) \[[@CR13], [@CR14]\]. Next to cervical cancer, the HR-HPV has also been linked to a large proportion of other kinds of cancers (anus, vulva, vagina and penis) and a growing number of head and neck tumors \[[@CR15]--[@CR19]\]. So far, \> 150 different HPVs have been characterized and completely sequenced. Of all types, about 40 are sexually transmitted and infect the genitalia \[[@CR17], [@CR20]--[@CR23]\]. HPV types 16 and 18 are notably responsible for \> 70% of all cervical cancer cases worldwide \[[@CR15], [@CR24], [@CR25]\].

Cervical cancer is curable if detected at its early stage. Premature detection cervical lesion is valuable as it develops slowly preceding cervical cancer which typically takes over a period 10 years \[[@CR26]\]. These precursor lesions called the cervical intraepithelial neoplasia (CINs) could be detected by a variety of methods \[[@CR27]\]; the most frequently used one is cytology, but there are other alternative methods such as HPV DNA tests and visual inspection with acetic acid (VIA) \[[@CR15]\], the latter being practiced primarily in resource limited settings \[[@CR15]\]. However, cytology and HPV-DNA based tests are widely available in most developed nations \[[@CR28], [@CR29]\]. HPV DNA testing is being introduced in some countries as an adjunct to cytology ('co-testing') or as the primary screening test to be followed by a secondary test such as cytology or measurement of HR-HPV E6/E7 gene products \[[@CR15], [@CR30], [@CR31]\].

Getting tools with reasonable diagnostic performance remains a challenge in the fight against cervical cancer globally. Given the inadequacy of existent methods, plus limitations in the use of both cytology and HPV DNA test (including but not limited to the sensitivity/specificity issues and the inability to indicate the risk of progression to cancer), there has long been interest in the development of new screening tools in cervical cancer \[[@CR28], [@CR29]\]. Many discovery approaches to find HPV associated cervical cancer screening biomarkers are currently underway, of which the HR-HPV *E6/E7 mRNA* test is a promising non-invasive biomarker for the detection of high grade cervical lesion (CIN2+) enabling detection of the HPV infection and simultaneously predicting the change of cervical lesions \[[@CR32]--[@CR40]\]. This is because continuous expression of E6/E7 oncogenes of HR-HPVs is necessary for the development and maintenance of the dysplastic phenotype \[[@CR41]\].

It is known that the synergistic effect of the E6 and E7 proteins results in a disturbance of cell cycle regulation, apoptosis prevention, and the transformation and maintenance of neoplastic and dysplastic cells \[[@CR42]\]. The overexpression of the E6 and E7 proteins, which inactivate the p53 and pRB respectively, can be detected by testing for the E6/E7 mRNA transcripts which is a potential biomarker (proxy indicator) for an increased risk of disease progression to the level of cancer \[[@CR43]--[@CR46]\]. The E6/E7 mRNA test can therefore help in avoiding aggressive procedures (biopsies and over-referral of transient HPV infections) as well as lowering patient's anxiety and the follow-up period as well \[[@CR34]\].

The detection of HR-HPV E6/E7 mRNA is being tested as the potential biomarker to elucidate the oncogenic role of HPV in cancer of the cervix and other kind of tumors in general \[[@CR30], [@CR35], [@CR36], [@CR39], [@CR40], [@CR42]\]. However, there is quite limited systematically reviewed data on the diagnostic role of different HPV E6/E7 mRNA tests for detection of CIN2+, using histology as a gold standard test. Specifically, the test performance of Aptima, Quantivirus and PreTect Proofer was assessed. The two tests (Aptima, Quantivirus) are able to detect the E6/7 mRNA from the same 14 HPV types, however, one of these tests (Aptima) is FDA approved and has a number of publications in the literature, whereas the other one (Quantivirus) has no clinical population based study published so far and only few entries in the web. The third test (PreTect Proofer) is only able to detect the E6/7 mRNA of five HPV types.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Protocol registration {#Sec4}

In accordance with the PRISMA guidelines, our systematic review protocol was submitted to the International Prospective Register of Systematic Reviews (PROSPERO) and registered with a registration number 'CRD42019123382'.

### Eligibility criteria {#Sec5}

Studies were selected based on the following criteria; *Study design*: we considered observational quantitative studies, like cross-sectional and cohort studies that reported the diagnostic performance of HPV E6/E7 mRNA assays for the detection of CIN2+. (CIN2+ refers to: histologically confirmed high grade lesions (CIN2, CIN3 and cancer)). *Participants*: We included studies that included women (cervical sample) having different kinds of cervical pathology. *Language and publication*: we included peer-reviewed journal articles published in English in the period of 2011 to 14 Jan 2019 with the outcome of interest reported in different countries.

### Information sources and search strategy {#Sec6}

This review was done following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA) guideline \[[@CR47]\]. Research papers were systematically searched in PubMed/Medline and SCOPUS using key words by combing using Boolean operator. Manual search from Google scholar and Google databases was also performed for grey literature; the last search was done on 14th of Jan, 2019. The reference lists of retrieved articles were probed (forward and back ward searching) to identify articles that were not retrieved from databases and our manual search. The first two authors; AD and DM searched the articles independently.

The domains of the search terms were Human Papillomaviruses, HPV, E6/E7 mRNA, and Cervical Intraepithelial Neoplasia. We combined Human Papillomaviruses and HPV with the Boolean operator "OR", and the result was combined with the other terms with "AND". Full search strategy for the two databases is annexed in Additional file [1](#MOESM1){ref-type="media"}.

### Study selection {#Sec7}

Research papers that reported the type of HPV E6/E7 mRNA diagnostic performance for the detection of CIN2+ were included. Searched articles were directly imported and handled using EndNote X5 citation manager (Thomson Reuters, New York, USA). Based on the PRISMA protocol, duplicated articles were excluded and the titles and abstracts of the remaining papers were screened independently for inclusion in full text evaluation by the first two authors. Differences between the reviewers were resolved through discussion.

### Data collection process and data items {#Sec8}

Data such as the name of the first author, year of publication, country where the study was conducted, age group of the study participants, type of women included in the study, CIN profile of the study participants, the proportion of CIN2+, type of HPV E6/E7 mRNA test used, the positivity rate of the mRNA test and its diagnostic performance (in terms of sensitivity, specificity, Positive Predictive value (PPV) and Negative Predictive Value (NPV)) were extracted from the included articles.

### Quality appraisal {#Sec9}

To assess the risk of bias, the Critical Appraisal Skills Programme (CASP) tool \[[@CR48]\] that developed to evaluate studies of diagnostic test accuracy was independently used by the first two authors. Of the twelve criterion of the tool, we eliminated three items because we felt that their scoring is difficult and rating the items would be more of subjective. Assessment of quality results was categorized but not summarized into a score as the method has little validity \[[@CR48]\].

### Data synthesis {#Sec10}

The extracted data were fed into a Microsoft Excel and presented in terms of 1) CIN profile of the study subjects, 2) the proportion of CIN2+, 3) the proportion of mRNA test result 4) diagnostic performance of mRNA test to detect CIN2+ (sensitivity, specificity, PPV and NPV). Owing to the presence of a large amount of clinical heterogeneity of the included articles and as most of the papers didn't present the 2 × 2 table, pooling of the diagnostic performance of mRNA tests was not possible. Instead, we performed a descriptive presentation of these elements (using range) to compile a best evidence synthesis for E6/E7 mRNA HPV testing in the detection of CIN2+. A systematic narrative synthesis was provided in which summary results were presented using text, table and figures. Descriptive statistics, such as: simple counts, ranges and percentages were used to describe the findings.

Results {#Sec11}
=======

Search results {#Sec12}
--------------

From the systematically searched databases and other sources, a total of 231 articles were retrieved and sequentially screened. After removing 88 duplicates, the 143 were screened by title then 52 were removed. Consequently, 53 were removed by abstract and 9 by full text with justifiable reasons. Finally, a total of 29 studies met our inclusion criteria. Screening was based on the PRISMA flow chart which was adapted from the PRISMA guidelines \[[@CR49]\] (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1The PRISMA flow diagram of literature selection

Characteristics of the included studies {#Sec13}
---------------------------------------

The characteristic of the included articles is summarized in (Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}). The studies were reported from 13 different countries in Europe, Asia and the United States of America. We didn't find articles reported in Latin America and Africa, in particular. The number of participants in each included study varied from 60 to 9451. Seven studies did not report the age of the study participants. The included studies employed a total of 23,576 study participants (age range, 15--84 years) who had different cervical pathologies. The studies were of varying methodological quality, and were predominately performed in a secondary screening setting (i.e women or cervical samples were subjected to HPV E6/E7 mRNA testing secondary to having positive cervical cytology and/or positive HPV DNA test). Similarly, diverse histological findings were reported ranging from normal histology to cervical cancer (Table [1](#Tab1){ref-type="table"}). Table 1Characteristics of the included studies, 2011--18Author (s), YearCountry\#Partici-pantsAge group, medianStudy population characteristicsHistology profilesRatnam, 2011Canada141815--80, 30.6Women referred to colposcopy and those routinely screenedNormal = 651, CIN1 = 366, CIN2 = 120, CIN2 + =401, CIN3 = 281Waldstrom, 2011Denmark40516--65, 32Three years archived liquid-based samples, all with a diagnosis of LSILCIN2 + =67, CIN3 + =33Fan, 2018China192No dataPatients with abnormal cytology results and/or high-risk HPV infectionCIN1- = 41, CIN1 = 54, CIN2 = 28, CIn3 = 53, cancer = 16Han,2018China197No dataWomen with abnormal cytological or HPV test resultsCIN1- = 80, CIN1 = 16, CIN2/3 = 50, Caner = 51Binnicker,2014USA350No dataResidual specimens with a cytologic result of ≥ atypical squamous cells of undetermined significance (ASC-US)CIN2 + =81, CIN3 + =41Broccolo,2013Italy30820--65A retrospective study on cervical cytology specimensNormal = 70, CIN1 = 159, CIN2 + =79Waldstrom, 2012Denmark23530--69, 42.2Women with ASC-US cytologyNormal = 86, CIN1 = 35, CIN2 = 21, CIN3 = 26, Cancer = 1Li,2017China318No dataWomen with ASCUS cytology attending routine outpatient primary cervical screeningNormal = 169, CIN1 = 74, CIn2 = 40, CIN3 = 16, cancer = 19Benevolo,2011Italy46417--78, 32Hybrid Capture 2 (HC2)-positive patients, who underwent colposcopy\<CIN2 = 49, CIN2 + =49, SCC = 9Wang, 2019Korea56320--84, noLiquid-based cytology samplesNormal = 51, CIN1 = 75, CIN2 = 16, CIN3 = 40, cancer = 38Liu, 2014China335No dataWomen who underwent outpatient hospital-based gynecological screeningNormal = 30, CIN1 = 5, CIN2 = 1,CIn3 = 15, Cancer 41Iftner, 2015Germany945130--60Women undergoing routine cervical screening\<CIN2 = 513, CIN2 = 47, CIN3 + =43Sorbye, 2011Norway52025--69Post-colposcopy follow-up of women with negative or low-grade biopsyCIN2- = 396, CIN2 + = 124Duvlis, 2015Macedonian41319--78Women that come for cervical cancer screeningNormal = 10, CIN1 = 22, CIN2 = 20, CIN3 = 9Castro, 2013Spain16518--75, 34.8Women with endocervical samples harboring HPV 16 and/or 18 DNACIN2- = 93, CIN2 + = 72Pierry, 2012USA24619--75Women in a higher risk urban screening populationNormal = 137, CIN1 = 64, CIN2 = 25, CIN3 = 20Alaghehbandan, 2013Canada136015--80, 30.7women with a history of abnormal cytology referred to colposcopyNormal = 635, CIN1 = 345, CIN2 + =380, Cancer = 10Clad, 2011Germany424No dataWomen referred to colposcopy due to an abnormal Pap smearNormal = 108, CIN1 = 64, CIN2 = 89, CIN3 = 150, Cancer = 13Varnai, 2018Germany6621--66, 34.6Office based screening population who were HPV-DNA positive for at least one of the following HR- HPV types: HPV 16, 18, 31, 33 and 45Normal = 6, CIN2 = 5, CIN3 = 22Coquillard, 2011USA2049No dataWomen both low and high riskNormal = 1694, CIN1 = 78 CIN2 + =73Shen, 2013China27216--77, 37Women with abnormal colposcopyCIN1- = 80, CIN2 = 6, CIN3 + =25Li, 2016China18622--68Patients underwent colposcopyNormal = 32, CIN1 = 51, CIN2/3 = 71, cancer = 32Liu, 2017China380\> 30Women who were associated with high risk of cervical virus infectionNormal = 159, CIN1 = 68, CIN2 = 74, CIN3 = 68, cancer = 11Benevolo, 2011Italy161018--83, 39.5Retrospective analysis of women underwent an E6/E7 mRNA test on cervical samplesNormal = 74, CIN1 = 282, CIN2 = 120, CIN3 = 86, cancer = 24Liu, 2018Japan17122--76, 33Women with pathologically-diagnosed CIN or cervical carcinomaCIN1 = 16, CIN2 = 33, CIN3 = 83, SCC = 39Persson, 2014Sweden21923--60, 32HR-HPV-positive women diagnosed with atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL)Normal = 56, CIN1 = 69, CIn2 = 37, CIN3+ 36Sorbye, 2011Norway29725--69Women with ASC-US and LSCIN1- = 53, CIN2 + =69Andersson, 2011Sweden20421--79, 32Women who were undergoing gynecological screening or had been admitted to a referral centerNormal = 45, CIN1 = 33, CIn2 = 28, CIN3 = 31, Cancer 28Oliveira, 2013Portugal55418--73, 33Women were referred for opportunistic screening and for evaluation of HPV associated lesionsNormal = 131, CIN1 = 128, CIn2 = 129, CIN3 = 146, Cancer = 14Table 2The proportion of HPV E6/E7 mRNA test result and its diagnostic performance of against histology, 2011--18Author (S)Prevalence of CIN2+, n (%)HPV DNA testHPV E6/E7 mRNA testmRNA test positivity rate, n(%)Performance of E6/E7 mRNA testSen%Spe%PPV%NPV%AU-ROC%Ratnam, 201128.30%Hybrid Capture 2 (HC2)Aptima964 (68%)96.346.240.096.7Waldstrom, 201167(16.5)noneAptima271 (67%)92.538.222.996.3Fan, 201897 (50.5)HC2Fluorescence in situ hybridization (FISH)no data91.581.682.790.990.9Han,2018101 (51.3)No dataNo dataNo data85.266.772.98174.95Binnicker,201481(23.1)HC2APTIMA230 (65.7%)91.44232.194.2Broccolo,201379 (25.6)Quantitative real-time PCRPreTect HPV-Proofer115 (37.3)7781.766.988Waldstrom, 201248 (55.8)Linear ArrayAptima103 (31.7%)87.57840.897.3Li,201785 (26.7)HC2QuantiVirus HPV E6/E7 RNA 3.0;177 (70.2)88.236.433.989.368.5Benevolo,201149 (10.6)HC2Pretect HPV-Proofer165 (36%)72733992Wang, 2019104 (47.3)HPV DNA chip testOptimygene HR-HPV RT-qDx assay,219 (38.9)85.982.578.287.4Liu, 201457 (61.9)NoQuantivirus®135 (40.3)71.974.38261.978Iftner, 201590 (14.9)HC2Aptima464 (4.9%)87.896.121.199.8Sorbye, 2011124 (23.8)NoPreTect HPV-Proofer52 (27.1)89.192.577.396.4Duvlis, 201529 (47.5)NoNucliSENS-EasyQ® (PreTect Proofer)74 (17.9)93.1506288.9Castro, 201372 (43.6)Nested PCRNucliSENS-EasyQ® (PreTect Proofer)96 (58.2)84.18090.988.9Pierry, 201245 (18.3)none(HPV OncoTect899271Alaghehbandan, 2013380 (27.9)HC2PreTect HPV-Proofer525 (38.6)76.168.75589.1Clad, 2011252 (59.4)HC2Aptima274 (65)91.775Varnai, 201827 (81.8)PCR-based typingPreTect HPV-Proofer38 (58)95558186Coquillard, 201173 (28.1)HC2Quantivirus®No data848578--Shen, 201331 (27.9)HC2Quantivirus®200 (73.5)82.415.522.27563.8Li, 2016103 (55.4)HC2Quantivirus®138 (74.2)91.34768.181.375.9Liu, 2017153 (40.3)noneQuantivirus®275 (72.4)93.462.140.597.3Benevolo, 2011230 (39.2)HC2PreTect HPV-Proofer166 (10.3)83458091Liu, 2018155 (90.6)SepaGene kitRT-PCR assay95 (55.6)55509177Persson, 201473 (36.9)Linear Array GenotypingAPTIMA162 (74)78.12536.567.4Sorbye, 201169 (23.2)NonePreTect HPV-Proofer97 (32.7)94.2866798Andersson, 201187 (56.1)NoneReal-time PCRNo data91686791Andersson, 201187 (56.1)NonePreTect HPV-ProoferNo data75777081Oliveira, 2013295 (53.8)HC2NucliSENS EasyQ® (PreTect Proofer)305 (55.1)79.372.676.775.5

Among those participants who had cervical histological examination, the proportion of CIN2+ was between 10.6 and 90.6%. The reported proportion of positive mRNA test varied from 10.3 to 74.2%. With regard to the type of HPV E6/E7 test methods, 11 studies evaluated the PreTect Proofer, 7 studies evaluated the APTIMA HPV assay, 6 studies evaluated the Quantivirus® HPV assay and the remaining studies each evaluated Fluorescence in situ hybridization (FISH), Optimygene HR-HPV RT-qDx assay, HPV OncoTect, RT-PCR assay based on consensus primers and real-time PCR assay. A study \[[@CR50]\] evaluated both real-time PCR assay and PreTect Proofer. On top of this, about 13 studies compared HPV E6/E7 mRNA testing to the Hybrid Capture 2 (HC2) DNA test (Digene/Qiagen), two studies compared the mRNA test to Linear Array (Roche Diagnostics), two studies compared the mRNA test to DNA PCR testing, one study used SepaGene kit, one study used HPV DNA chip test and one study used QuantiVirus®HPV DNA Diagnostic Kit. The rest didn't compare the mRNA test with HPV DNA test. The agreement between HPV-DNA and HPV-E6/E7 mRNA test in the detection of cervical lesions (which varied from 77.6 to 92.5%) was reported by only 8 studies \[[@CR39], [@CR51]--[@CR57]\] (Table [2](#Tab2){ref-type="table"}).

Risk of bias {#Sec14}
------------

Ratings of the study quality for each of the nine domain-based critical appraisal skills program (CASP) \[[@CR48]\] criteria to make sense of a diagnostic test study are presented in Additional file [2](#MOESM2){ref-type="media"}. The risk of bias for each individual domain was rated as 'Yes', 'No' or 'Can't tell'. The assessment of quality results was categorized not scored otherwise. The mRNA test predictive values were not reported by Clad et al. \[[@CR56]\]. Otherwise we felt that all the included studies had no major methodological uncertainties.

Diagnostic performance of HPV E6/E7 mRNA testing to detect CIN2+ {#Sec15}
----------------------------------------------------------------

Due to the difference in clinical presentation of subjects (considerable clinical heterogeneity of the study participants by the included studies), pooling the diagnostic performance data was not possible. In its place, we compiled a best evidence synthesis for HPV E6/E7 mRNA HPV testing to detect high grade cervical lesions (CIN2+) using descriptive statistics.

The diagnostic performance of the three most common mRNA testing tools as compared with histologically confirmed high-grade cervical intraepithelial neoplasia (CIN2+) as an endpoint was as follows; 1) PreTect Proofer; median sensitivity 83%; ranged 72--95%, median specificity 73%; range 45--92.5%, median PPV 70%; range 39--90.9%, median NPV 88.9%; range 81--98%, 2) APTIMA assay; median sensitivity 91.4%; range 78.1--96.3%, median specificity 46.2%; range 25--96.1%, median PPV 34.3%; range 21--40.8% and median NPV 96.3%; range 67.4--99.8% and 3) Quantivirus®: median sensitivity 86.1%; range 71.9--93.4%, median specificity 54.6%; range 36.4--85%, median PPV 54.3%; range 22.2--82%, median NPV 89.3%; range 61.9--97.3%.

Only six studies \[[@CR51], [@CR58]--[@CR62]\] reported the area under the receiver operating characteristic (ROC) curve for diagnosing high-grade cervical lesions (CIN2+) by HPV E6/E7 mRNA tests considering histology as a gold standard. The reported area under the curve varied from 63.8 to 90.9% (the curve was to the left of the diagonal) with overall mRNA test median sensitivity, 87.7%, range 55--96.3%; median specificity 70.7%, range 25.5--96.1%; median PPV 67%, range 21.1--91%; and median NPV 83.7%, range 77--99.8% (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec16}
==========

There is a previous review on the performance of HPV mRNA test by Burger et al. \[[@CR63]\] which was published in 2010. Our review is an update of the latest knowledge on the test performance of HPV E6/E7 mRNA test, compiled from articles published since 2011. We included double number of studies with varying methodological quality but our finding is in line with this review. Hence, together with the previous review \[[@CR63]\], our finding would be considered for further large scale studies to generate bold data on the clinical applicability of the test.

In the present review, women were tested for the HPV E6/E7 mRNA predominately secondary to having positive cervical cytology and/or positive HPV DNA test. Similarly, diverse histological findings were reported ranged from normal histology to cervical cancer. The HPV E6/E7 mRNA tests detected 10.3 to 74.2% proportions of cervical lesions from participants who had different level of cervical pathology. A study by Liu et al. showed that the positivity rate of HPV E6/E7 mRNA test increased with the severity of cytological or histological findings \[[@CR60]\] in which all samples with high-grade lesions were positive for the HPV mRNA test as described previously \[[@CR40]\]. All grades of histological findings were reported in this review. Specifically, the proportion of CIN2+ was between 10.6 and 90.6%. This reflects the diverse spectrum of cervical pathologies of the participants employed by the included articles. Due to this heterogeneity of the employed participants by the included studies, the results of the HPV E6/E7 mRNA test performance have limited generalizability and conclusion should be considered with caution. Moreover, extreme diagnostic results were also reported, for example, the test specificity reported by Sorbye et al. \[[@CR64]\] was at (92.5%) and Persson et al. \[[@CR65]\] was at (25%). Similarly, extreme positive predicative values (PPVs) of the mRNA test were reported by Iftner et al. at 21.1% \[[@CR55]\] and Liu et al. at 91% \[[@CR66]\] in which the disparity might be resulted from a difference in the type of included study participants who had different cervical pathologies.

Our review report proved that the E6/E7 mRNA tests have diagnostic relevance to detect CIN2+, especially with good test specificity. This is consistent with a previous study \[[@CR63]\]. Recent evidences also showed that detection of the HPV E6/E7 mRNA transcripts may provide a higher specificity for the detection of high grade cervical lesions, since the oncogenic potential of HPV infection depends on the over expression of these two transcripts \[[@CR57]\] but the test methods lack either detection of all high-risk HPV genotypes (like, PreTect HPV-Proofer) or the capacity to specify the detected genotypes (like, APTIMA) \[[@CR50]\]. In general a high specificity and NPV of the E6/E7 HPV mRNA test \[[@CR35]\] can be translated into a low referral rate for colposcopy \[[@CR61]\], which is not commonly available, particularly in resource limited settings.

There are several HPV testing kits/products available \[[@CR67]\]. In our review, studies used the following kind of HPV E6/E7 mRNA testing products; PreTect Proofer (NorChip AS)/NucliSENS-EasyQ® (Biomerieux), APTIMA HPV assay, Quantivirus® HPV assay, Fluorescence in situ hybridization (FISH), Optimygene HR-HPV RT-qDx assay, HPV OncoTect, RT-PCR assay based on consensus primers and real-time PCR assay. The first two methods are commonly utilized tests in the field of HPV mRNA test; hence in this review out of 29 included studies 18 used these two methods.

Taking histology confirmed CIN 2+ as the disease endpoint to assess the clinical performance of the test, the sensitivity of APTIMA at (78.1--96.3%) was better than the PreTect HPV-Proofer (72 to 95%) and Quantivirus® (71.9--93.4%). However, in terms of specificity (45--92.5%) the PreTect HPV-Proofer was much better than these two tests. This might partly because, the PreTect HPV-Proofer detects only the mRNA of the five most common HPV types (HPV16, 18, 31, 33, and 45) hence is more specific than the APTIMA and Quantivirus® assays which detect mRNA of more genotypes. Targeting more genotypes makes the latter two methods rather more sensitive than the PreTect Proofer \[[@CR50]\]. Our review result is in line with this argument. On top of this, the reported AU-ROC curve by six of the articles \[[@CR51], [@CR58]--[@CR62]\] varied from 63.8 to 90.9% which reflects the usefulness of the test in discriminating women having CIN2 + .

In our review 8 studies \[[@CR39], [@CR51]--[@CR57]\] reported the agreement between HPV-E6/E7 mRNA and HPV-DNA testing for the detection of cervical lesions at 77.6--92.5%. Compared to DNA-based tests (the most common one was Digene Hybrid Capture 2 HPV DNA test) which indicate only the presence or absence of the virus, detecting HPV E6/E7 mRNAs gives more insight into viral activity and by implication, clinical relevance (correlate better with the severity of the lesion). Hence, the latter is a potential marker for the identification of women at risk of developing cervical carcinoma. Our review support the argument that the HPV E6/E7 mRNA assay could overcome the shortcoming of low specificity of DNA assays for clinical detection of high-grade cervical lesions \[[@CR35], [@CR68]--[@CR75]\].

The Burger et al. \[[@CR63]\] review on HPV mRNA test for the detection of cervical intraepithelial neoplasia, the reported sensitivities varied between 41 and 86% and 90--95% for the PreTect Proofer/Easy Q and APTIMA assay, respectively. Similarly, the reported specificities vary from 63 to 97% and 42--61% for the PreTect Proofer/Easy Q and APTIMA assay, respectively. These figures are almost in line with our reports. It is good to note that a higher specificity, especially in a triage setting may reduce the number of women that would be subjected to unnecessary conizations and expensive follow-up \[[@CR63], [@CR71]\] and patients psychologic burden associated with repeated HPV-DNA testing \[[@CR72]\]. However, an individual study by Shen et al. does not support the use of this assay in screening for cervical cancer prevention alone \[[@CR61]\].

A study by Yang et al. also showed that a woman tested positive for HPV E6/E7 mRNA had a higher risk of progressing to high grade cervical lesions. Whereas, women with a negative HPV E6/E7 mRNA can increase follow-up interval, by comprehensively considering their situation, thus, avoiding unnecessary colposcopy and reducing the rate of colposcopy and biopsy \[[@CR76]\]. In our review the overall mRNA test performance in terms of negative predicative value (NPV) was at (77--99.8%) which is in line with the above statement in which mRNA test had a very good negative prediction of women for high grade cervical lesions if they get tested negative. These help patients from unnecessary follow-up including the expensive colposcopy, diagnostic and therapeutic procedures \[[@CR64]\]. In contrary, women tested positive in the HPV E6/E7 mRNA test have a greater risk of malignant progression of cervical lesions and therefore needs more care and earlier check-ups \[[@CR77]\].

Limitations {#Sec17}
-----------

This systematic review presents the latest developments in the field of HPV E6/E7 mRNA test accuracy. We have included relatively adequate number of articles published in different countries employing a large number of study participants. However, our review result should be interpreted in light of a couple of shortcomings. The main drawback of our review is the lack of studies that employed similar and well-defined population with same cervical pathology characteristics. Hence, the review was suffered from heterogeneity of the studies and was not possible to pool the performance of the mRNA tests. Moreover, the decisive aim of cervical cancer screening is to detect cervical lesions that will develop into cancer. However, the use of histologically confirmed CIN2+ endpoint when evaluating mRNA accuracy represents a challenge because of the regression (false positive) or progression (false negative) of many confirmed lesions \[[@CR63]\]. Confining our inclusion criteria to include only articles published in English languages may introduce missing of relevant studies and reduced the precision of our results.

Conclusions {#Sec18}
===========

The reported test performance and the receiving operating characteristics curves implies that HPV E6/E7 mRNA testing has a diagnostic relevance to detect CIN2+ and could be considered in areas where there is no histological test facility. Further studies including its cost should be considered. Moreover, future research in the field should emphasis on the clinical translation (utility) of HPV E6/E7 mRNA tests using large consecutive cohorts of women, including participants from developing nations, representing a well-defined population for a specific type of cervical pathology.
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**Additional file 1.** Search strategy **Additional file 2.** Risk of bias summary result: review authors' judgements about each risk of bias item for included studies, 2011--18
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